3 Topic Commentaries

MAPK Inhibitors Restore CAR T-Cell Target in Thyroid Cancer Models

• 

  Saad J. Kenderian, M.B., Ch.B.

  Hematology/Oncology; Cellular Immunotherapy

  •

  Mayo Clinic

  We often think about engineering the immune cell to overcome resistance, This work shows another possibility.

  Source
• 

  Claudia Manriquez Roman, Ph.D.

  Cell and Gene Therapy Process Development

  •

  Mayo Clinic

  One of the key discoveries from our work is that antigen density matters. We showed that restoring TSHR expression with combination therapy can sensitize aggressive thyroid tumors to CAR-T cell attack, effectively turning a suboptimal target into a more vulnerable one. This approach may provide a new framework for enhancing CAR-T therapies across solid tumors where target expression is limited,

  Source
• 

  John A. Copland III, Ph.D.

  Cancer Biology and Translational Research

  •

  Mayo Clinic

  What’s exciting about this approach is that we're taking advantage of the cancer cell's own biology to restore TSHR expression by blocking MAPK signaling with molecular targeted drugs,

  Source